Avion Wealth’s Anixa Biosciences ANIX Stock Holding History

Avion Wealth’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	200	–	–	﹤0.01%	1417
2026 Q1	$0	Hold	200	–	–	﹤0.01%	1221
2025 Q4	$0	Hold	200	–	–	﹤0.01%	1210
2025 Q3	$0	Hold	200	–	–	﹤0.01%	1176
2025 Q2	$0	Hold	200	–	–	﹤0.01%	1137
2025 Q1	$0	Buy	+200	New	+$572	﹤0.01%	996
2024 Q4	–	Sell	-200	Closed	–	–	987
2024 Q3	$0	Buy	+200	New	+$615	﹤0.01%	976

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Avion Wealth's ANIX Position: Q2 2026 in Review

Avion Wealth held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 200 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Avion Wealth first reported a position in ANIX in Q3 2024 and has held it in 7 quarters since. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

Avion Wealth held 200 shares of Anixa Biosciences worth $0 as of Q2 2026.
Avion Wealth left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1417 holding.
Avion Wealth first reported a position in Anixa Biosciences in Q3 2024 and has held it in 7 quarters since.
63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.